## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	OVAL	
OMB Number:	3235-0	287
Estimated average	burden	
nours per response	e	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response:	s)																	
Name and Address of Reporting Person * Roivant Sciences Ltd.					2. Issuer Name and Ticker or Trading Symbol Immunovant, Inc. [IMVT]							5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner						
(Last) (First) (Middle) SUITE 1, 3RD FLOOR, 11-12 ST. JAMES'S SQUARE					3. Date of Earliest Transaction (Month/Day/Year) 08/02/2021							-	Office	er (give title belo	ow)	Other (specify	below)		
(Street) LONDON, X0 SW1Y 4LB				4. If	4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line)  _X_Form filed by One Reporting Person  Form filed by More than One Reporting Person						
(City)	-	(State)		(Zip)		,	<b>Fable</b>	I - No	n-D	Derivative	Secur	rities A	Acquii	red, Disp	osed of, or l	Beneficially	Owned		
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Ye		2A. Deemed Execution Date, any (Month/Day/Yea		Code		n	4. Securities Acquired or Disposed of (D) (Instr. 3, 4 and 5)		Benefic Report		Amount of Securities neficially Owned Following ported Transaction(s) str. 3 and 4)		Ownership Form: Direct (D)	of India Benefic Owner	Beneficial Ownership		
							Со	de	V	Amou	nt	(A) or (D)	Price	:			or Indirect (Inst (I) (Instr. 4)		4)
	Common Stock, \$0.0001 par value per share		<u>J(1)</u>			17,021,	276	A	<u>(1)</u>	73,388,664			D						
Kemmuel. I	Report on a s	срагате ппе	ioi each		· Deriv	ative Secur	ities A	cqui	Pe co the	ersons whomation with the contract of the cont	no rein this splay	s forn /s a c · Bene	n are urren ficiall	not requ tly valid	ction of inf uired to res OMB con	spond unle	ss	1474 (9	<del>)</del> -02)
1 77'41 6	2	2 75		24 D	` ' '	outs, calls,		nts, o	_					. 1	lo. D.:	0.31 1	C 10	1,,	N
Derivative Security	ivative Conversion or Exercise (Month/Day/Year) Execution Date, if Transaction Number and Code of (Month/Day/Year)		6. Date Exercisable and Expiration Date Month/Day/Year)		Amo Unde Secur	unt of crlying rities r. 3 and Derivative Security (Instr. 5)		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form of Derivat Securit Direct or India	of I Ber Ow (Ins D) ect	Beneficia Ownershi (Instr. 4)								
						Code V	(A)	(D)	E	ate xercisable		ration	Title	Amount or Number of Shares					

### **Reporting Owners**

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Roivant Sciences Ltd. SUITE 1, 3RD FLOOR 11-12 ST. JAMES'S SQUARE LONDON, X0 SW1Y 4LB		X					

#### **Signatures**

/s/ Marianne Romeo Dinsmore, as Authorized Signatory	08/02/2021
**Signature of Reporting Person	Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On August 2, 2021, Roivant and Immunovant, Inc. ("Immunovant") entered into a Share Purchase Agreement pursuant to which Roivant purchased 17,021,276 shares of Immunovant's common stock for an aggregate purchase price of \$200,000,000, in cash, representing a per share price of \$11.75.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.